science
Pancreatic Cancer Drug Shows Doubled Survival in Early Results
A medication called daraxonrasib produced more than double the survival time previously seen in pancreatic cancer patients. The drug also received FDA approval for an early access program and began shipping this week.
May 31, 11:46 AM·1m read1 source
ER
newscientist.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A medication for pancreatic cancer produced survival results more than double those previously recorded, according to data released today. Daraxonrasib is the compound associated with the reported gains.
The same drug became available through an FDA-approved early access program. Shipments to physicians began this week. No prior treatment for pancreatic cancer has shown comparable survival improvement, the report stated.
Transparency
How sources framed this
ER
ER
Single source — no framing comparison available.
CorroborationModerate · 1 source
